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doi:10.1016/j.pedneo.2011.03.003Background: Malignant ovarian tumors in children are relatively rare. We reviewed our 15-year
experience to understand their clinical presentations, managements, and prognoses.
Methods: There were 15 children who were diagnosed to have malignant ovarian tumors from
January 1994 to June 2009 in our hospital. The presenting symptoms, treatments, and
outcomes were obtained retrospectively from the medical records.
Results: The median age at presentation was 13 years. The most common presenting symptom
was abdominal pain, occurring in 10 patients (66.7%). The tumors were in the left side in 10
patients (66.7%). The pathologic diagnoses were yolk sac tumors in four patients, immature
teratomas in four, dysgerminomas in three, malignant mixed germ cell tumors in three, and
carcinosarcoma in one patient. According to the Federation Internationale de Gynecologie On-
cologique classification, seven girls had Stage I, one had Stage II, and seven had Stage III
disease. Thirteen patients received chemotherapy with platinum-based regimens. Three
patients died of their disease: one of yolk sac tumor, one of malignant mixed germ cell tumor,
and one of carcinosarcoma. They all had Stage III disease at diagnosis. The 10-year overall
survival and disease-free survival rates were 77% and 69%, respectively.
Conclusions: Pediatric malignant ovarian tumors were highly curable disease if they were not
in the advanced stage at presentation. Earlier consideration of malignant ovarian tumor in the
differential diagnosis of young girls with abdominal pain is important.
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Pediatric malignant ovarian tumors 1411. Introduction and abdominal computed tomography, was performed in allOvarian cancer is the fifth leading cause of death from
cancer in women and the leading cause of death from
gynecological cancer. It is thought of as a killer because
early disease cause minimal, nonspecific, or even no
symptoms so that most patients are diagnosed at an
advanced stage. In adult women, most primary ovarian
tumors arise from epithelial cells. This typically occurs in
postmenopausal women. Epithelial ovarian cancer includes
serous tumor, endometrioid tumor, and mucinous cys-
tadenocarcinoma.1 The 5-year survival rate for all stages of
ovarian cancer is 45%.2 In contrast, in children, malignant
ovarian tumors are rare, germ cell tumors comprise most of
them, and prognosis is better than for adult women.3 There
is limited information about such tumors in children. Thus,
we reviewed medical records to understand the clinical
behavior of this tumor.
2. Materials and Methods
From January 1994 to June 2009, 15 consecutive pediatric
patients were diagnosed to have malignant ovarian tumors
by histology in our institution. We recorded their symp-
toms, related examinations, surgical treatments, histopa-
thology, treatment regimens, and responses. We used the
Federation Internationale de Gynecologie Oncologique
classification system for staging: Stage I, disease limited to
ovaries; Stage II, tumor extended to the pelvis; Stage III,
intraperitoneal dissemination; and Stage IV, distant
metastases. Disease-free survival and overall survival (OS)
estimates were calculated by Kaplan-Meier analysis.
Disease-free survival period was defined from the date of
complete remission to the date of recurrence, death, or
last disease-free visit (months). OS period was defined from
the date of registration to the date of death or last visit
(months). Data were updated to December 31, 2009.3. Results
The patient data are summarized in Table 1. The median
age at presentation was 13 years (range, 3e17 years). The
most common presenting symptoms, in descending order,
were abdominal pain in 10 patients (66.7%), abdominal
fullness in 6 (40%), abdominal mass in 3 (20%), fever in 3
(20%), and body weight loss in 2 (13.3%). Other symptoms
included decreased appetite, pale face, and constipation.
Ten patients (66.7%) had left ovarian involvement, and five
patients (33.3%) had right ovarian involvement.
Tumor markers of alpha-fetoprotein (AFP) and b-human
chorionic gonadotropin (b-hCG) were measured at diagnosis
in 11 patients. The serum AFP and b-hCG were tested by
radioimmunoassay. We found that seven patients had high
AFP levels (range, 54.2emore than 10,000 ng/mL; five of
them had more than 10,000 ng/mL, three of those five had
20,334 ng/mL, 79,658 ng/mL, 397,160 ng/mL, respectively;
for two patients, no further dilution was done). There were
three patients who had high b-hCG levels (range,
23.9e165 mU/mL). Two patients had normal AFP and b-hCG
levels. Diagnostic imaging, including abdominal echogrampatients.
All patients received surgery. Ten patients had received
unilateral salpingo-oophorectomy. Three patients had
received excision of tumor, and one patient received
unilateral oophorectomy. Bilateral salpingo-oophorectomy
was performed in one patient. The pathologic diagnoses
were yolk sac tumor in four, immature teratoma in four,
dysgerminomas in three, malignant mixed germ cell tumors
in three, and carcinosarcoma in one patient. Germ cell
tumors comprised 93% of all malignant tumors. According to
the Federation Internationale de Gynecologie Oncologique
staging system, seven girls were classified as Stage I, one as
Stage II, and seven as Stage III.
Thirteen of 15 patients received chemotherapy with
platinum-based regimens. Twelve of them received bleo-
mycin, etoposide, and cisplatin regimen, and the patient
who had the diagnosis of carcinosarcoma received ifosfa-
mide and cisplatin regimen. Number of cycles for chemo-
therapy was ranging from two to six. No major acute
toxicity and no treatment-related deaths were observed.
One patient who was diagnosed with Stage I yolk sac
tumor was found to have relapsed with peritoneal seeding
after being off of chemotherapy for 25 months. She
received further chemotherapy with cisplatin, ifosfamide,
and etopisde for six cycles and had no evidence of disease
till the date we analyzed. Three patients died of their
disease: one of yolk sac tumor, one of mixed germ cell
tumor, and one of carcinosarcoma. They were all in Stage III
at diagnosis. Two of them received bleomycin, etoposide,
and cisplatin regimen for four cycles, and the other
received ifosfamide and cisplatin for three cycles. The 10-
year OS and disease-free survival rates were 77% and 69%,
respectively (Figure 1).4. Discussion
Malignant ovarian tumors in children are relatively rare,
representing approximately 1% of all childhood malignant
tumors.3 There were only 15 pediatric malignant ovarian
tumor patients treated in our institution during the 15-year
study period. These tumors were mostly diagnosed in
adolescents between 16 years and 20 years.4 In our study,
the median age at presentation was 13 years.
The presenting symptoms are often nonspecific. The
most common presenting symptoms in our patients were
abdominal pain, followed by abdominal fullness and
abdominal mass. Patients will become acutely symptomatic
if they undergo hemorrhage, torsion, or rupture.5,6 Most of
the malignant ovarian tumors presented as unilateral
masses. Metastasis at diagnosis and bilateral involvement
were rare, consistent with other reports.7
Most malignant ovarian tumors in childhood and
adolescence are germ cell tumors. Norris and Jensen8
reviewed 353 ovarian tumors in young females and found
germ cell tumors composed 80% of the preadolescent
malignant ovarian tumors. Hassan et al9 reported germ cell
tumors comprised 49.1% of all malignant ovarian tumors in
girls through age 19. Schultz et al10 found that 67.5% of
pediatric malignant ovarian tumors were germ cell tumors.
In our study, germ cell tumors comprised 93% of all
Table 1 Clinical characteristics of pediatric malignant ovarian tumor patients
Patient Age
(y/o)
S/S Tumor
site
Tumor marker
(before operation)
Pathology Treatment OP
method
C/T regimen
(cycles)
Stage Current
status
Survival
(mo)
1 14 Pain R A[, B[, C[, CEA N YST Sþ C/T ATHþ BSO PEB (4) III DOD 10
2 13 Fullness L A[, B N, C[, CEA N YST Sþ C/T LSO PEB (4) III Alive >173
3 14 Fullness, anorexia L A[, B N, C[, CEA N YST Sþ C/T LSO PEB (5) I Alive, relapse
25 mo later
>76
4 8 Pain L NA YST Sþ C/T LSO PEB (4) I Alive >77
5 5 Pain, body weight loss L A[, B NA, C[, CEA[ Immature teratoma Sþ C/T LSO PEB (4) II Alive >7
6 3 Pain, mass L A[, B NA, C NA, CEA NA Immature teratoma S LSO No I Alive >36
7 15 Pain R NA Immature teratoma Sþ C/T RO PEB (6) I Alive >109
8 8 Pain, mass, body
weight loss, anorexia
R A N, B N, C NA, CEA N Immature teratoma S Excision No I Alive >87
9 14 Fullness L A N, B[, C[, CEA N Dysgerminoma Sþ C/T LSO PEB (3) I Alive >172
10 11 Mass R A N, B[, CN, CEA N Dysgerminoma Sþ C/T RSO PEB (4) I Alive >82
11 17 Pain L NA Dysgerminoma Sþ C/T LSO PEB (2) III Alive >2
12 11 Fullness, fever R NA MMGCT Sþ C/T Excision PEB (4) III DOD 21
13 15 Pain, fullness, fever L A[, B N, C NA, CEA NA MMGCT Sþ C/T Excision PEB (6) III Alive >51
14 6 Pain, fullness, fever L A[, B NA, C NA, CEA NA MMGCT Sþ C/T LSO PEB (6) III Alive >24
15 13 Pain L A N, B NA, C[, CEA NA Carcinosarcoma Sþ RTOþ C/T LSO IP (3) III DOD 6
AZ alpha-fetoprotein; ATHZ abdominal total hysterectomy; BZ beta-human chorionic gonadotropin; BSOZ bilateral salpingo-oophorectomy; CZ CA-125; CEAZ carcinoembryonic
antigen; C/TZ chemotherapy; DODZ died of disease; IPZ ifosfamide and cisplatin; LZ left; LSOZ left salpingo-oophorectomy; MMGCTZmalignant mixed germ cell tumor;
moZmonths; NZ normal; NAZ not available; OPZ operation; PEBZ platinum, etoposide, and bleomycin; RZ right; ROZ right oophorectomy; RSOZ right salpingo-oophorectomy;
RTOZ radiotherapy; SZ surgery; S/SZ symptoms/signs; y/oZ year old; YSTZ yolk sac tumor.
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Figure 1 Overall survival and disease-free survival in 15
children with malignant ovarian tumors.
Pediatric malignant ovarian tumors 143malignant tumors, and more than 80% of the patients were
aged 15 or less. Therefore, germ cell tumor tends to occur
in younger girls and nongerm cell tumor proportion is
increased as the age increases.
Tumor markers are important for evaluating malignant
ovarian tumors for diagnosis, relapse, and follow-up.11
Various tumor markers have been used for monitoring the
clinical status of malignant germ cell tumors, including
AFP, b-hCG, human placental lactogen, pregnancy-specific
b1 glycoprotein, fibronectin, transferrin, a-antitrypsin,
carcinoembryonic antigen, alkaline phosphatase, lactate
dehydrogenase, cancer antigen-125, and neuron-specific
enolase.12,13 Among these tumor markers, AFP and b-hCG
are the most used. AFP can be used as a tumor marker for
endodermal sinus tumor, embryonal carcinoma, and
malignant mixed germ cell tumor. Elevated levels of b-hCG
can be seen in some patients with pure dysgerminoma,
mixed germ cell tumor, embryonal carcinoma, and ovarian
choriocarcinoma.14
There were five patients who had AFP level more than
10,000 ng/mL at diagnosis in our study. Three patients were
diagnosed as having yolk sac tumor, and the other two were
diagnosed as having malignant mixed germ cell tumor. Four
of these five patients were classified as Stage III. The
number of patients was small, yet high AFP at diagnosis
seemed to mean higher stage. The levels of AFP after
treatment were reported to reflect the treatment
response.15 Most patients in our study had AFP levels
declined to normal range within 3 months after treatment.
Nevertheless, one patient whose AFP increased rapidly 3
months after discontinuation of chemotherapy died 2
months after relapse, and another had AFP level elevated
to 114 ng/mL before she was found to have relapsed tumor.
The treatment of ovarian tumors is complete surgical
staging, followed by chemotherapy in cases beyond Stage I.
Total tumor resection when possible is recommended by all
studies, and salpingo-oophorectomy is the suggested
surgical resection because cancer cells may spread to the
fallopian tube through ovarian lymphatics.7,16,17 Whetheradjuvant chemotherapy can improve outcomes for patients
with resected Stage I tumor containing immature neural
elements and presence of foci of yolk sac tumor remains
controversial. Marina et al18 reported that 1 of the 13 girls
with immature ovarian teratoma and microscopic foci of
yolk sac tumor developed recurrent disease, whereas Wil-
liams et al19 suggested that three courses of adjuvant
cisplatin-based chemotherapy should be given to all well-
staged patients with completely resected ovarian germ cell
tumors to prevent recurrence. In our study, there were
three patients diagnosed with Stage I immature teratoma
who received complete resection. Of them, two did not
receive chemotherapy, whereas one did receive chemo-
therapy; all were in continuous disease-free state till the
date when we analyzed.
The combination of cisplatin, etoposide, and bleomycin
has been used with excellent cure rates.20e22 Rogers et al21
reported patients with Stage I tumors had 6-year OS and
event-free survival of 95.1% and 95.1%, respectively, and
patients with Stage II disease had OS and event-free survival
of 93.8% and 87.5% when treated with four cycles of
cisplatin, etoposide, and bleomycin. In the St. Jude’s
experience, the response to treatment of malignant ovarian
tumors of low stage was excellent when compared with
patients with advanced disease.23 In addition to achieving
higher cure rates, platinum-based combination therapies
were reported to be able to preserve normal menstrual
function and maintain fertility with healthy offspring.24,25 In
this aspect, we lacked sufficient data to analyze.
We also analyzed various factors, including age,
histology, stage, and levels of tumor marker, to see which
one(s) could determine prognosis. There was no conclusive
result, which maybe because of the limited number of
patients. Cushing et al22 reported that AFP greater than
10,000 ng/mL and b-hCG greater than 5000 mU/mL at
diagnosis were unfavorable prognostic factors, whereas
Murugaesu et al26 stated that increasing stage and elevated
AFP and b-hCG at presentation were independent adverse
prognostic factors and elevated AFP during treatment
meant high risk of treatment failure.
In conclusion, pediatric malignant ovarian tumor is
a highly curable disease if not in the advanced stage at
presentation. Earlier consideration of malignant ovarian
tumor in the differential diagnosis of young girls with
abdominal pain seems important.References
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